1,122 results on '"Amadori, S."'
Search Results
2. PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
3. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia
4. The impact of Mild Behavioral Impairment on the individual’s level of psychological, social, and occupational functioning
5. S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
6. S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
7. Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes
8. Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients
9. High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
10. A procedure for the identification of the SLS material model from dynamical experimental measurements
11. LABNET AML: AN EFFICIENT NETWORK THAT CONNECTS HEMATOLOGY CENTERS AND LABORATORIES FOR A HIGH-LEVEL DIAGNOSTIC/PROGNOSTIC WORKUP OF AML
12. YNK01, an Oral Cytosine Arabinoside Derivative in Acute Myeloid Leukemia and Chronic Myeloid Leukemia
13. Intensified Early Therapy for Childhood Acute Myeloid Leukemia: Pilot Studies of the AIEOP Cooperative Group
14. P.0304 Circulating insulin levels and serotonin transporter expression in obese subjects
15. Therapy of Adult Acute Lymphoblastic Leukemia. Preliminary Results of the GIMEMA ALL/0288 Study
16. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
17. Therapy of Childhood Acute Myelogenous Leukemia: An Update of the AIEOP/LAM 8204 Study
18. Anelasticity in nanostructured MgH 2–Mg: Correlation with hydrogen sorption kinetics
19. Low temperature anelasticity in Ti6Al4V alloy and Ti6Al4V–SiC f composite
20. Expression of Cellular Oncogenes in Primary Cells from Human Acute Leukemias
21. Translocation and Rearrangement of c-myc into Immunoglobulin α Heavy Chain Locus in Primary Cells from Acute Lymphocytic Leukemia
22. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia
23. Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia
24. Experimental identification of the parameters of a multilayer coating architecture
25. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL
26. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
27. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial
28. A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy
29. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
30. Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
31. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia
32. P.024 Prevalence of obsessive-compulsive traits and of problematic Internet use in professional tennis players
33. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
34. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
35. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
36. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial
37. 6-Phosphogluconate dehydrogenase deficiency in an Italian family
38. Automated resonant vibrating-reed analyzer apparatus for a non-destructive characterization of materials for industrial applications
39. O 6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O 6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro
40. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes
41. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods
42. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
43. CD34+/CD110+ and CD34+/CD133+ cells in the apheresis collections of multiple myeloma patients predict early and long-term haematopoietic recovery after peripheral blood stem cell transplantation: O383
44. Anelasticity and Structural Stability of ECAP Processed Al-Mg-Si Alloys Investigated by Mechanical Spectroscopy
45. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
46. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia
47. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report: O133
48. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
49. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials
50. Placental/Umbilical Cord Blood: Experience of St. Eugenio Hospital Collection Center
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.